Pregabalin Capsule
Product Images NDC 70518-4743

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4743). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin 150 mg Capsule C-V oral dosage form carton label showing quantity of 30 capsules. The label states this is a prescription drug under federal law, repackaged by RemedyRepack Inc., with storage instructions and a QR code. The original manufacturer is Camber Pharma, Inc.*

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A survival-type curve graph illustrating the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 200 mg, 100 mg, and 25 mg taken three times a day compared to placebo. The curves show decreasing patient improvement percentages as pain improvement increases, with higher doses of Pregabalin generally associated with higher patient improvement percentages.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A Kaplan-Meier survival curve comparing estimated percentage of subjects without LTR over 180 days for Pregabalin versus Placebo. The x-axis represents days, and the y-axis shows the estimated percentage of subjects without LTR, with distinct solid and dashed lines for Pregabalin and Placebo, respectively.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph comparing the percentage of subjects improved over time from baseline to Week 12, with separate lines for Pregabalin and placebo. The x-axis represents the percent improved, and the y-axis represents the percent of subjects improved. The Pregabalin line shows a higher percentage of subjects improved compared to the placebo line.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph depicting the percent of subjects improved over a range of percent improvement from baseline to Week 16 BOCF. The graph compares Pregabalin (solid line) and Placebo (dashed line) across the x-axis labeled 'Percent Improved from Baseline to Week 16 BOCF' and the y-axis labeled 'Percent of Subjects Improved'.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A chart plotting percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg taken three times a day with placebo. The graph shows two curves illustrating patient response over increasing pain improvement percentages.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph showing the percent of patients improved compared to the percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and Placebo, with each group represented by a different line pattern. The y-axis represents percent of patients improved, ranging from 0 to 100%, and the x-axis shows percent improvement in pain from baseline, ranging from 0 to 100%.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph illustrating the percentage of patients improved versus the percent improvement in pain from baseline. It compares outcomes for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and a placebo group, showing the trend of patient improvement across varying levels of pain improvement.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

This chart compares the percent improvement in pain from baseline against the percent of patients improved, showing three lines for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The Y-axis represents the percent of patients improved, ranging from 0 to 100%, and the X-axis shows percent improvement in pain from baseline, also ranging from 0 to 100%. Vertical lines mark specific improvement thresholds at 30% and 50%.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar chart comparing responder rates (%) from two clinical studies, labeled Study E1 and Study E3. The x-axis shows treatment groups with placebo and various daily doses of the drug administered twice daily (BID) or thrice daily (TID). The y-axis represents responder rate percentages, ranging from 0% to 60%. Study E1 includes placebo and 50, 150, 300, and 600 mg/day BID groups; Study E3 includes placebo and 600 mg/day BID and TID groups. Significant differences from placebo are indicated.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

Dose-response chart showing seizure reduction as median percentage change from baseline for Pregabalin across four studies. The x-axis indicates dose in mg/day (0 to 600 mg), and the y-axis shows seizure reduction percentage (0 to 60%). Data points for four studies with different markers demonstrate statistically significant seizure reduction at increasing doses compared to placebo, with p-values noted on the graph.*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A bar chart depicting responder rates (%) for Pregabalin at two dosages (2.5 mg/kg/day and 10 mg/kg/day) compared to placebo. The chart shows the number of subjects (N) in each group below the bars, with responder rates increasing from placebo to higher doses.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph showing the percent of patients improved relative to percent improvement in pain from baseline. The graph compares Pregabalin at daily doses of 600 mg, 450 mg, and 300 mg, and a placebo. The y-axis represents the percent of patients improved, ranging from 0 to 100%, and the x-axis represents percent improvement in pain, ranging from greater than 0 to 100%.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure of Pregabalin showing its molecular configuration with an amino group, methyl group, and carboxylic acid group on a carbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.